Literature DB >> 19089324

Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases.

Evanthia Mergia1, Doris Koesling, Andreas Friebe.   

Abstract

The NO/cGMP signalling cascade has an important role in smooth muscle relaxation, inhibition of platelet aggregation and neuronal transmission. Although the function of the main NO receptor GC (NO-GC) is well established, the particular tasks of the NO receptor isoforms (NO-GC1 and NO-GC2) are unclear and NO targets other than NO-GC have been postulated. Mice deficient in either NO receptor isoform or with a complete lack of NO-GC are now available and allow new insights in NO/cGMP signalling. The first reports about the KO strains show that, outside the neuronal system, the NO-GC isoforms can substitute for each other, and that amazingly low cGMP increases are sufficient to induce smooth muscle relaxation. In the neuronal system, however, the NO-GC isoforms obviously serve distinct functions as both isoforms are required for long term potentiation. Analysis of the complete NO-GC KO provides evidence that the vasorelaxing and platelet-inhibiting effects of NO are solely mediated by NO-GC. Thus, NO-GC appears to be the only NO receptor in these two systems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19089324     DOI: 10.1007/978-3-540-68964-5_3

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  8 in total

1.  Contributions of nitric oxide synthases, dietary nitrite/nitrate, and other sources to the formation of NO signaling products.

Authors:  Alexandra B Milsom; Bernadette O Fernandez; Maria F Garcia-Saura; Juan Rodriguez; Martin Feelisch
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

2.  Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling.

Authors:  Mizanur M Rahaman; Anh T Nguyen; Megan P Miller; Scott A Hahn; Courtney Sparacino-Watkins; Soma Jobbagy; Nolan T Carew; Nadiezhda Cantu-Medellin; Katherine C Wood; Catherine J Baty; Francisco J Schopfer; Eric E Kelley; Mark T Gladwin; Emil Martin; Adam C Straub
Journal:  Circ Res       Date:  2017-06-05       Impact factor: 17.367

3.  Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.

Authors:  Justin M Percival; Candace M Adamo; Joseph A Beavo; Stanley C Froehner
Journal:  Handb Exp Pharmacol       Date:  2011

Review 4.  cGMP becomes a drug target.

Authors:  Jens Schlossmann; Elisabeth Schinner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-03       Impact factor: 3.000

5.  Identification of residues in the heme domain of soluble guanylyl cyclase that are important for basal and stimulated catalytic activity.

Authors:  Padmamalini Baskaran; Erin J Heckler; Focco van den Akker; Annie Beuve
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

Review 6.  What is the real physiological NO concentration in vivo?

Authors:  Catherine N Hall; John Garthwaite
Journal:  Nitric Oxide       Date:  2009-07-12       Impact factor: 4.427

7.  Crystal structures of the catalytic domain of human soluble guanylate cyclase.

Authors:  Charles K Allerston; Frank von Delft; Opher Gileadi
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

8.  cGMP Imaging in Brain Slices Reveals Brain Region-Specific Activity of NO-Sensitive Guanylyl Cyclases (NO-GCs) and NO-GC Stimulators.

Authors:  Stefanie Peters; Michael Paolillo; Evanthia Mergia; Doris Koesling; Lea Kennel; Achim Schmidtko; Michael Russwurm; Robert Feil
Journal:  Int J Mol Sci       Date:  2018-08-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.